Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Investing Activities: 2012-2025

Historic Cash from Investing Activities for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $95.6 million.

  • Agios Pharmaceuticals' Cash from Investing Activities fell 61.90% to $95.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.9 million, marking a year-over-year decrease of 53.17%. This contributed to the annual value of $363.4 million for FY2024, which is 51.70% up from last year.
  • Agios Pharmaceuticals' Cash from Investing Activities amounted to $95.6 million in Q3 2025, which was up 21.01% from $79.0 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Cash from Investing Activities ranged from a high of $1.9 billion in Q1 2021 and a low of -$298.1 million during Q2 2021.
  • Its 3-year average for Cash from Investing Activities is $80.9 million, with a median of $79.0 million in 2025.
  • Examining YoY changes over the last 5 years, Agios Pharmaceuticals' Cash from Investing Activities showed a top increase of 1,628.95% in 2021 and a maximum decrease of 1,422.29% in 2021.
  • Agios Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$94.4 million in 2021, then skyrocketed by 187.85% to $83.0 million in 2022, then climbed by 15.14% to $95.5 million in 2023, then slumped by 151.47% to -$49.2 million in 2024, then plummeted by 61.90% to $95.6 million in 2025.
  • Its Cash from Investing Activities was $95.6 million in Q3 2025, compared to $79.0 million in Q2 2025 and $112.6 million in Q1 2025.